Clinical trial
A Phase II Study to Assess the Safety, Tolerability and Efficacy of SPD503 Administered to Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00150592 is registered in ClinicalTrials.gov with Shire as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study to Assess the Safety, Tolerability and Efficacy of SPD503 Administered to Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Lead sponsor
- Shire
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 12, 2005
- Completion date
- October 5, 2005
- Enrollment
- 182 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.